TEL AVIV, Feb 13 (Reuters) - Israel-based Teva Pharmaceutical Industries said on Tuesday it had anticipated and planned for a second generic competitor to its multiple sclerosis treatment Copaxone to enter the market in 2018.



Latest News

Daily Mail: Video: Arsene Wenger on Manchester City game in Carabao cup final

Daily Mail: Video: Dancer overcomes crippling scoliosis to pursue her passion

Daily Mail: Video: Giant blaze destroys 3-story apartment building in California

Daily Mail: Ballroom champ dances again after scoliosis surgery

Daily Mail: At least 18 killed after twin blasts and gunfire in...

Daily Mail: What is RHOBH star Kyle Richards’s net worth?

Daily Mail: Road closed after car and lorry crash

Daily Mail: Alex Jones and Maya Jama spotted at the BBC

CTV News: Funeral arrangements made for Howard McCurdy

CTV News: Tour bus driver fined for fatal crash in Banff National Park

CNBC: Instacart discovers a bug that withheld tips from shoppers and overcharged users

BBC: Bullish Trump jokes about hiding his bald spot

ABC: Japanese students voted to select official mascots for Tokyo 2020 Olympic Games

AP: Trump says son-in-law's clearance is up to Kelly

Daily Mail: US STOCKS-Stocks climb as Fed eases rate concern, tech...

Daily Mail: U.S. to move to 'phase 2' if N.Korea sanctions don't...

Daily Mail: Trump: chief of staff Kelly to decide on Kushner...

Daily Mail: 300 residents and 45 apartment units are destroyed in fire

FOX: Father who sparked fire that killed son gets prison

FOX: The Latest: Spokesman off staff list after profane tweet

FOX: Last teen pleads guilty in death of passenger hit by sandbag

ABC: Former Trump aide Rick Gates formally pleads guilty to two counts

Reuters: EU's Tusk warns Poland must stop anti-Semitic remarks